| Literature DB >> 23981144 |
Pamela J Hill1, Ayome Abibi, Robert Albert, Beth Andrews, Moriah M Gagnon, Ning Gao, Tyler Grebe, Laurel I Hajec, Jian Huang, Stephania Livchak, Sushmita D Lahiri, David C McKinney, Jason Thresher, Hongming Wang, Nelson Olivier, Ed T Buurman.
Abstract
The tRNA-(N(1)G37) methyltransferase (TrmD) is essential for growth and highly conserved in both Gram-positive and Gram-negative bacterial pathogens. Additionally, TrmD is very distinct from its human orthologue TRM5 and thus is a suitable target for the design of novel antibacterials. Screening of a collection of compound fragments using Haemophilus influenzae TrmD identified inhibitory, fused thieno-pyrimidones that were competitive with S-adenosylmethionine (SAM), the physiological methyl donor substrate. Guided by X-ray cocrystal structures, fragment 1 was elaborated into a nanomolar inhibitor of a broad range of Gram-negative TrmD isozymes. These compounds demonstrated no activity against representative human SAM utilizing enzymes, PRMT1 and SET7/9. This is the first report of selective, nanomolar inhibitors of TrmD with demonstrated ability to order the TrmD lid in the absence of tRNA.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23981144 DOI: 10.1021/jm400718n
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446